Hellow guys, Welcome to my website, and you are watching What is the future for AML patients who cannot be treated with current therapy?. and this vIdeo is uploaded by VJHemOnc – Video Journal of Hematology & HemOnc at 2017-07-28T04:33:02-07:00. We are pramote this video only for entertainment and educational perpose only. So, I hop you like our website.
| Name | What is the future for AML patients who cannot be treated with current therapy? |
| Video Uploader | Video From VJHemOnc – Video Journal of Hematology & HemOnc |
| Upload Date | This Video Uploaded At 28-07-2017 11:33:02 |
| Video Discription | Shyamala Navada, MD, from Tisch Cancer Institute, New York, NY, US, discusses what the results from the Phase I/II trial evaluating the effectiveness of oral rigosertib in combination with azacitidine for the treatment of acute myeloid leukemia (AML) (NCT01926587) represents in terms of future treatments for AML. Here, she explains that this combination regimen may become a new therapeutic option for elderly AML patients who cannot tolerate standard induction therapies, as well as those with myelodysplastic syndrome (MDS). This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain. |
| Category | Education |
| Tags | AML | Subject: Acute Myeloid Leukemia | Medicines: Rigosertib | Medicines: Azacitidine | Speaker: Shyamala Navada | Event: EHA 2017 | Format: Interview |
